Literature DB >> 15854741

Angiotensin-converting enzyme (ACE) interacts with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice.

Maarten van den Buuse1, Thomas W Zheng, Lesley L Walker, Derek A Denton.   

Abstract

A renin-angiotensin system, separate to that in the periphery, has been found in the brain. Angiotensin-converting enzyme (ACE) is crucial in the synthesis of angiotensin II, breakdown of bradykinin and the hydrolysis of several other neuropeptides such as enkephalin, substance P, dynorphin and neurotensin. Changes in the levels of ACE have been found in brains of schizophrenia patients, suggesting an involvement of ACE in the illness which awaits further investigation. Prepulse inhibition (PPI) has been suggested to be an operational measure of sensorimotor gating and is disrupted in patients with schizophrenia. We found that ACE knockout mice have increased startle responses but no differences in baseline PPI compared to wildtype controls. Treatment with the dopamine receptor agonist, apomorphine, or the dopamine-releasing drug, amphetamine, produced significant disruption of PPI in control mice but not in ACE knockout mice. Pretreatment with the ACE inhibitor, captopril, which itself did not affect PPI, caused a reduction in the effect of apomorphine on PPI, similar to that seen in the ACE knockout mice. These data suggest an important role of ACE substrates in modulating dopaminergic mechanisms involved in PPI. Further studies are needed to ascertain if angiotensin or other neuropeptides are involved in these interactions and to investigate the neurochemical mechanism behind these effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15854741     DOI: 10.1016/j.neulet.2005.01.009

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery.

Authors:  Rong Xu; QuanQiu Wang
Journal:  J Biomed Inform       Date:  2015-07-04       Impact factor: 6.317

Review 2.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

3.  Brain Angiotensin II AT1 receptors are involved in the acute and long-term amphetamine-induced neurocognitive alterations.

Authors:  Natalia Andrea Marchese; Emilce Artur de laVillarmois; Osvaldo Martin Basmadjian; Mariela Fernanda Perez; Gustavo Baiardi; Claudia Bregonzio
Journal:  Psychopharmacology (Berl)       Date:  2015-11-28       Impact factor: 4.530

4.  Genomic survey of prepulse inhibition in mouse chromosome substitution strains.

Authors:  M P Leussis; M L Frayne; M Saito; E M Berry; K A Aldinger; G N Rockwell; R P Hammer; A E Baskin-Hill; J B Singer; J H Nadeau; P Sklar; T L Petryshen
Journal:  Genes Brain Behav       Date:  2009-07-21       Impact factor: 3.449

5.  A study in first-episode psychosis patients: does angiotensin I-converting enzyme (ACE) activity associated with genotype predict symptoms severity reductions after treatment with the atypical antipsychotic risperidone?

Authors:  João V Nani; Caroline Dal Mas; Camila M Yonamine; Vanessa K Ota; Cristiano Noto; Sintia I Belangero; Jair J Mari; Rodrigo Bressan; Quirino Cordeiro; Ary Gadelha; Mirian A F Hayashi
Journal:  Int J Neuropsychopharmacol       Date:  2020-07-22       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.